Bio Techne Company Top Insiders

TECH Stock  USD 53.14  0.04  0.08%   
Under 58% of Bio Techne's corporate insiders are selling. The analysis of insiders' sentiment of trading Bio Techne Corp stock suggests that many insiders are alarmed at this time. Bio Techne employs about 3.1 K people. The company is managed by 24 executives with a total tenure of roughly 42 years, averaging almost 1.0 years of service per executive, having 129.17 employees per reported executive.
Charles Kummeth  CEO
CEO and President and Director

Insider Sentiment 42

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-04-29April McClain DelaneyAcquired @ 50.5
2025-04-09April McClain DelaneyAcquired @ 54.07
2025-04-08Robert Bresnahan, Jr.Disposed @ 48.81
2025-04-01Julie JohnsonDisposed @ 57.35
2025-02-25Robert Bresnahan, Jr.Acquired @ 64.22
2025-02-14Amy E HerrDisposed 1860 @ 65.96View
2025-01-27Kim KeldermanDisposed 13392 @ 77.29View
Monitoring Bio Techne's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Bio Techne's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Bio Techne Corp. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Bio Techne's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Bio Techne Management Team Effectiveness

The company has return on total asset (ROA) of 0.0524 % which means that it generated a profit of $0.0524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0653 %, meaning that it created $0.0653 on every $100 dollars invested by stockholders. Bio Techne's management efficiency ratios could be used to measure how well Bio Techne manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Bio Techne's Other Current Assets are increasing as compared to previous years. The Bio Techne's current Total Current Assets is estimated to increase to about 745.5 M, while Other Assets are projected to decrease to under 8.8 M.
The Bio Techne's current Net Income Applicable To Common Shares is estimated to increase to about 344.5 M, while Common Stock Shares Outstanding is projected to decrease to under 169.2 M.

Bio Techne Workforce Comparison

Bio Techne Corp is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 87,337. Bio Techne holds roughly 3,100 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.11 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.14 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.14.

Bio Techne Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Techne insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Techne's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bio Techne insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Bio Techne Notable Stakeholders

A Bio Techne stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bio Techne often face trade-offs trying to please all of them. Bio Techne's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bio Techne's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Charles KummethCEO and President and DirectorProfile
MD MBAPresident GenomicsProfile
William GeistPresident SegmentProfile
James CPAExecutive CFOProfile
James HippelCFO and VP of Fin.Profile
Gary LathamVP CTOProfile
Robert GavinSr. VP of Protein Platforms DivisionProfile
Shane BohnenGeneral VPProfile
Lynne HohlfeldSenior DivisionProfile
Luca CicchettiManaging DirectorProfile
Brenda JDGen VPProfile
Martin WirtzSenior DevelopmentProfile
Cheryl BethuneSenior OfficerProfile
David CFASenior DevelopmentProfile
Gerry AndrosVice MarketingProfile
Bernie AndrussSenior DivisionProfile
Kim KeldermanPres GenomicsProfile
Evett KrukaSenior DivisionProfile
Dylan MalayterSenior DivisionProfile
David ClairIR Contact OfficerProfile
Kevin SmythSenior OfficerProfile
Steven SilvermanSenior ExperienceProfile
Brenda EversonSenior OfficerProfile
Steve CrouseSenior DivisionProfile

About Bio Techne Management Performance

The success or failure of an entity such as Bio Techne Corp often depends on how effective the management is. Bio Techne management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. Bio-Techne operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3000 people.

Bio Techne Workforce Analysis

Traditionally, organizations such as Bio Techne use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bio Techne within its industry.

Bio Techne Manpower Efficiency

Return on Bio Techne Manpower

Revenue Per Employee373.9K
Revenue Per Executive48.3M
Net Income Per Employee54.2K
Net Income Per Executive7M
Working Capital Per Employee147.8K
Working Capital Per Executive19.1M

Complementary Tools for Bio Stock analysis

When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
CEOs Directory
Screen CEOs from public companies around the world
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio